Who are C. difficile vaccine formulation 1.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Plegisol In Plastic Container, Plegisol In Plastic Container, Pf-07941944, PF-07220060 + PF-07104091 combination dose escalation, Zithromax, Licensed Influenza Vaccine 2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/c-difficile-vaccine-formulation-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

C. difficile vaccine formulation 1. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

C. difficile vaccine formulation 1. (c-difficile-vaccine-formulation-1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine.

marketed Vaccine Not specified Vaccine Live · refreshed every 30 min

Target snapshot

C. difficile vaccine formulation 1. (c-difficile-vaccine-formulation-1) — Pfizer Inc..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
C. difficile vaccine formulation 1. TARGET	c-difficile-vaccine-formulation-1	Pfizer Inc.	marketed	Vaccine	Not specified
Plegisol In Plastic Container	Sodium Chloride	Baxter	marketed	Electrolyte solution	Not specified	1965-01-01
Plegisol In Plastic Container	Sodium Chloride	Baxter	marketed	Electrolyte solution	Not specified	1965-01-01
Pf-07941944	pf-07941944	Pfizer	marketed	Small molecule	Not specified
PF-07220060 + PF-07104091 combination dose escalation	pf-07220060-pf-07104091-combination-dose-escalation	Pfizer	marketed	Not specified	Not specified
Zithromax	Azithromycin	Pfizer Inc.	marketed	Macrolide	Not specified in label
Licensed Influenza Vaccine 2	Licensed Influenza Vaccine 2	BioNTech	marketed	Vaccine	Not specified

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vaccine class)

GlaxoSmithKline · 16 drugs in this class
Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
Pfizer · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Henogen · 3 drugs in this class
Pfizer Inc. · 2 drugs in this class
Sanofi · 2 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
BioNTech · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). C. difficile vaccine formulation 1. — Competitive Intelligence Brief. https://druglandscape.com/ci/c-difficile-vaccine-formulation-1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing